Page 88 - An Evidence Review of Active Surveillance in Men With Localized Prostate Cancer

Table 5. Monitoring criteria in protocols with curative intent in chronological order of starting enrollment year (continued)
Center, Country Monitoring Gleason # biopsy cores PSA Imaging Behavioral Additional laboratory Triggers for
[Pubmed ID] schedule score /% cores indication tests interventions
Enrollment years
ProtecT, UK 116 PSA every 3 mo – referred to √ – – – The aim was “to
[19603015] in year 1 and biopsy if a PSA identify
ever 6 mo ≥3 ng/mL; developing
2000-2008 thereafter rebiopsy was cancers early
not routine enough to allow
treatment with
surgery or
j
radiotherapy”
(implied using
PSA level or
change and/or
rebiospy results
as triggers)
Dana-Farber PSA and DRE ≥7 20-core biopsy; √ – – – Patients with
k
Cancer Institute, every 6 mo; ≥3 positive progression
US 117 biopsy every 12 cores, or >50% were offered
[21167525] to 18 mo of any core surgery or
involved with radiotherapy.
2000-2010 cancer
Kagawa Medical PSA every 2 mo – Rebiopsy did not PSA DT <2 yr – – – PSA DT <2 yr
Univ., Japan 118 for 6 mo, every 3 fit initial after 6 mo after 6 mo;
[18272471] mo thereafter; pathology (based on all rebiopsy did not
Re-biopsy at 1 yr criteria (i.e., 1-2 PSA or most fit initial
2002-2003 (no data beyond positive cores recent 1 yr) pathology
1 yr) per 6-12 criteria
systematic
biopsy cores)
Cleveland clinic, PSA every 6-12 √ √ √ – – – Considering
US 119 mo, surveillance multiple
[21256549] biopsy usually parameters
every 2 yr or (PSA and PSA
2004-2009 sooner kinetics,
changes in DRE,
quantity of
cancer in biopsy
specimens, and
biopsy Gleason
score)

45